Dosage Forms

Reshaping Dosage Forms

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Frontrunners in Bispecific Antibodies

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Tackling Common Problems in Tableting and Tooling

March 01, 2013

The tableting science anti-research (TSAR) project seeks to understand why certain formulations stick to tablet tooling.

Concerns and Innovations in Tablet Splitting and Scoring

March 01, 2013

A roundtable discussion of the challenges and innovations in tablet splitting featuring Freeman Technology, Accu-Break Pharmaceuticals, and Medelpharm.

The Ph.Eur. approach to tablet splitting

March 01, 2013

An alternative chapter has been added to the European Pharmacopoeia for dosage uniformity.

Setting the Bar in Highly Potent API Manufacturing

February 27, 2013

Custom manufacturers with expertise in highly potent API production discuss the latest issues and technology developments in the field.

Growth of Bio-Process Systems Alliance Reflects Rising Interest in Single-Use Technologies

February 27, 2013

Kevin Ott, executive director of the Bio-Process Systems Alliance, discusses the latest trends and issues surrounding single-use technologies and the role of his association.

AAIPharma CEO Discusses Parenteral Manufacturing

February 27, 2013

AAIPharma Services CEO Patrick Walsh talks about the parenterals market and the drivers for his company's recent expansion of its sterile-manufacturing capabilities.

Sanofi's Six-In-One Pediatric Vaccine Recommended for European Approval

February 26, 2013

The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi's six-in-one pediatric vaccine for marketing authorization.

Merck and Samsung Bioepis Form Biosimilars Development and Commercialization Agreement

February 20, 2013

Merck and Samsung Bioepis have formed an agreement to develop and commercialize multiple prespecified and undisclosed biosimilar candidates.

BARDA Continues to Support Protein Sciences' Cell-Based Vaccine Programs

February 19, 2013

Protein Sciences announced that the Biomedical Advanced Research and Development Authority (BARDA) will continue to support the company?s influenza vaccines program.

Tracking Growth in Biologics

February 02, 2013

The share of biologic-based drugs in the global pharmaceutical market is on the rise.